Departamento de Neurologia, Faculdade de Medicina da Universidade de São Paulo (FMUSP), Av. Enéas de Carvalho Aguiar, 255, 5o andar, sala 5084, Cerqueira César, São Paulo, 05403-900, Brazil.
Department of Neurosciences, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.
J Neurol. 2018 Mar;265(3):708-713. doi: 10.1007/s00415-018-8736-8. Epub 2018 Jan 30.
The most common causes of congenital myasthenic syndromes (CMS) are CHRNE mutations, and some pathogenic allelic variants in this gene are especially frequent in certain ethnic groups. In the southern region of Brazil, a study found the c.130dupG CHRNE mutation in up to 33% of families with CMS. Here, we aimed to verify the frequency of this mutation among individuals with CMS in a larger cohort of CMS patients from different areas of Brazil and to characterize clinical features of these patients. Eighty-four patients with CMS, from 72 families, were clinically evaluated and submitted to direct sequencing of the exon 2 of CHRNE. The c.130dupG mutation was found in 32 patients (23 families), with 26 patients (19 families, 26.3%) in homozygosis, confirming its high prevalence in different regions of Brazil. Among the homozygous patients, the following characteristics were frequent: onset of symptoms before 2 years of age (92.3%), little functional restriction (92.3%), fluctuating symptoms (100%), ocular muscle impairment (96.1%), ptosis (100%), limb weakness (88.4%), response to pyridostigmine (100%), facial involvement (77%), and bulbar symptoms (70.8%). The pretest probability of finding at least one allele harbouring the c.130dupG mutation was 38.1%. Selecting only patients with impaired eye movement together with limb weakness and improvement with pyridostigmine, the probability increases to 72.2%. This clinical pre-selection of patients is likely a useful tool for regions where CHRNE mutations have a founder effect. In conclusion, the CHRNE mutation c.130dupG leads to fairly benign natural course of the disease with relative homogeneity.
最常见的先天性肌无力综合征(CMS)的病因是 CHRNE 突变,该基因的一些致病变异体在某些种族中尤为常见。在巴西南部地区,一项研究发现,CMS 患者的家系中高达 33%存在 CHRNE 基因 c.130dupG 突变。在此,我们旨在验证巴西不同地区更大 CMS 患者队列中该突变的频率,并对这些患者的临床特征进行分析。对 72 个 CMS 患者家系的 84 名 CMS 患者进行了临床评估,并对 CHRNE 外显子 2 进行了直接测序。在 32 名患者(23 个家系)中发现了 c.130dupG 突变,其中 26 名患者(19 个家系,26.3%)为纯合子,证实了其在巴西不同地区的高发生率。在纯合子患者中,以下特征很常见:症状在 2 岁前出现(92.3%),功能受限小(92.3%),症状波动(100%),眼肌受累(96.1%),上睑下垂(100%),肢体无力(88.4%),对吡啶斯的明有反应(100%),面肌无力(77%)和球部症状(70.8%)。发现至少一个携带 c.130dupG 突变等位基因的先验概率为 38.1%。选择仅存在眼运动障碍、肢体无力和吡啶斯的明改善的患者,概率增加至 72.2%。对于 CHRNE 突变具有奠基者效应的地区,这种患者的临床预筛选可能是一种有用的工具。总之,CHRNE 突变 c.130dupG 导致疾病具有相对均一的良性自然病程。